

Smart Matrix Limited**Successful funding round raises GBP 2.54m****Strong interest by existing shareholders to follow on**

30 March 2018, Smart Matrix Limited ('SML' or 'the Company'), the advanced wound healing company, today announces that both new and existing shareholders are investing an additional GBP 2.54m.

SML has 50 shareholders, of whom seven are former CEOs or Chairmen of FTSE 100 companies. During previous funding rounds, the Company already raised nearly GBP 6m. Its two largest investors are Downing, the UK regulated investment manager, and Francis Gugen, the Company's Executive Chairman.

Swen Lorenz, member of the board: "The additional equity is extending the cash runway of the Company to mid-2019 or even further into the future. The confidence our investors are placing into the Company's work puts SML into a strong position for carrying out the work that, ultimately, is aimed at an exit, trade sale or IPO of the Company."

SML is currently preparing a series of clinical trials, which are scheduled to commence during Q4 / 2018.

For further information, please contact:

Smart Matrix Limited

Francis Gugen, Executive Chairman

gugenf@smartmatrix.co.uk, Tel: +44 (0) 7785 326 291

About Smart Matrix Limited

Smart Matrix Limited ('SML') was spun out of the Restoration of Appearance and Function Trust ("RAFT"), a medical research charity based at Mount Vernon hospital, Middlesex, UK, in late 2011.

SML is focused on the commercialisation of products from a proprietary platform technology developed by RAFT scientists based on a matrix manufactured from fibrinogen and thrombin, natural products of the healing process, and alginate, a product derived from seaweed and widely used in wound care products.

The first product developed from this platform is Smart Matrix®, a scaffold designed to help the body close surgical wounds and regenerate lost skin. Smart Matrix® works by encouraging the growth of skin cells and new blood vessels, critical to healthy healing.

SML has an exclusive, world-wide license to Smart Matrix® and first right of refusal to license other products developed by RAFT that are based on the underlying

platform technology. The envisaged applications of the platform include potentially acute wound care, bone healing and regeneration, dental and soft-tissue repair.

For further information see: www.smartmatrix.co.uk